Naloxegol for the treatment of opioid-induced constipation

Area of Science:

• Pharmacology
• Gastroenterology
• Clinical Therapeutics

Background:

• Chronic opioid use is increasing, leading to a rise in opioid-induced constipation (OIC).
• Opioid-induced constipation is a significant clinical challenge impacting patient quality of life.
• Naloxegol, a peripherally-acting µ-opioid receptor antagonist, was developed to address OIC.

Purpose of the Study:

• To summarize published data and meeting presentations on naloxegol's efficacy and safety in treating OIC.
• To evaluate naloxegol's mechanism of action in inhibiting gastrointestinal opioid effects while preserving central analgesia.
• To review clinical trial data on naloxegol for OIC treatment.

Main Methods:

• Review of animal studies investigating naloxegol's peripheral and central effects.
• Analysis of human pharmacodynamic studies to confirm the proposed mechanism of action.
• Evaluation of Phase II and Phase III clinical trials in patients with non-cancer OIC.

Main Results:

• Animal and human studies confirmed naloxegol inhibits gastrointestinal opioid effects while preserving central analgesic properties.
• Phase II and III studies demonstrated naloxegol's efficacy in treating OIC, with the 25 mg once-daily dose showing consistent results.
• No signs of opioid withdrawal were observed. Adverse events were primarily mild and transient gastrointestinal issues. Long-term safety studies revealed no new adverse events.

Conclusions:

• Naloxegol is an effective treatment for opioid-induced constipation.
• The 25 mg daily dose of naloxegol demonstrates consistent efficacy for OIC.
• Naloxegol presents a favorable safety profile with manageable side effects for OIC treatment.